These Luci-TRE-SMN transgenic mice harbor the "new" pBI-L-SMN(B) transgene designed to express both luciferase and a full-length human SMN gene under the control of a bi-directional tet-responsive promoter. These "new" Luci-TRE-SMN(B) mice allow high levels of both luciferase and full-length human SMN expression to be regulated by the addition/removal of dox, and offer a means to generate mutant mice for Tet-Off/Tet-On and/or fluorescent protein studies of Spinal Muscular Atrophy (SMA).
Arthur H.M. Burghes, The Ohio State University
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Reporter, Inducible, Inserted expressed sequence, Humanized sequence) |
Mice hemizygous for the "new" pBI-L-SMN(B) transgene ("new" Luci-TRE-SMN(B) transgene mice) are viable and fertile, with no reported phenotypic abnormalities. These Luci-TRE-SMN transgenic mice express luciferase and a full-length (exons 1-8) human SMN gene under the control of a bi-directional tet-responsive promoter (TRE or tetO). When bred with another mouse expressing tetracycline-controlled transactivator protein (tTA) or reverse tetracycline-controlled transactivator protein (rtTA), simultaneous luciferase and SMN expression can be regulated with the tetracycline analog doxycycline (dox) in the resulting double mutant offspring. These Luci-TRE-SMN transgenic mice are useful to generate mutant mice for Tet-Off/Tet-On and/or fluorescent protein studies of Spinal Muscular Atrophy.
The Luci-TRE-SMN transgene was created by Dr. Arthur HM Burghes (The Ohio State University). The Luci-TRE-SMN transgenic construct used here ["new" pBI-L-SMN(B)] was designed with a luciferase sequence on one side, and a full-length human SMN2 cDNA sequence (encoding exons 1-8) on the other side of the Pbi-1 bi-directional tetracycline-responsive promoter. The 1.37 kb human SMN2 cDNA sequence was derived via RT-PCR performed on total RNA isolated from SMA type 1-derived patient fibroblast cells (Coriell Institute GM 3813; shown to express both full-length and truncated SMN2 transcripts). Compared to the "old" pBI-L-SMN construct, the "new" pBI-L-SMN(B) construct used here has a 31 bp sequence (including a hemagglutinin epitope tag sequence) deleted between the Pbi-1 promoter and 5' end of SMN2 cDNA, as well as additional SMN2 exon 8 UTR sequence downstream of the SMN2 cDNA. The Pbi-1 promoter contains the Tet-responsive element (TRE; seven copies of the 42-bp tet operator sequence [tetO]) placed between two minimal CMV enhancer-less promoters. The "new" Luci-TRE-SMN(B) transgene was microinjected into the male pronucleus of FVB/N embryos. Founder mice were bred with Camk2a-tTA mice (FVB background; see Stock No. 003010) to determine which lines had high dox-inducible levels of luciferase and SMN in brain. The high-expressing "new" Luci-TRE-SMN(B) founder line was identified and used to create the Tg(SMN2)89; Smn1+/-; Tg(SMNΔ7)4299; ROSA26rtTA; "new" Luci-TRE-SMN(B) mice (on a mixed FVB/N and C57BL/6 genetic background) that was sent to The Jackson Laboratory Repository as Stock No. 017597). Upon arrival, some mice were bred with FVB/NJ inbred mice (Stock No. 001800) for several generations to remove the other transgenes/mutations. The resulting mice harboring only the "new" Luci-TRE-SMN(B) transgene were assigned Stock No. 017600.
Expressed Gene | SMN2, survival of motor neuron 2, centromeric, human |
---|---|
Expressed Gene | luc, luciferase, firefly |
Site of Expression | When bred to mice expressing a tetracycline transactivator (tTA) or reverse transactivator (rtTA), doxycycline induction results in the expression of luciferase and SMN expression in transactivator expressing tissues of the offspring. |
Allele Name | transgene insertion, Arthur H M Burghes |
---|---|
Allele Type | Transgenic (Reporter, Inducible, Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | |
Gene Symbol and Name | Tg(tetO-SMN2,-luc)#bAhmb, transgene insertion, Arthur H M Burghes |
Gene Synonym(s) | |
Promoter | tetO, tet operator, |
Expressed Gene | SMN2, survival of motor neuron 2, centromeric, human |
Expressed Gene | luc, luciferase, firefly |
Site of Expression | When bred to mice expressing a tetracycline transactivator (tTA) or reverse transactivator (rtTA), doxycycline induction results in the expression of luciferase and SMN expression in transactivator expressing tissues of the offspring. |
Strain of Origin | FVB/N |
Chromosome | UN |
Molecular Note | The tetracycline response element with two minimal CMV promoters drives inducible expression of human SMN (exons 1 through 8) and a luciferase gene. |
Mutations Made By | Arthur Burghes, The Ohio State University |
Some Tg(SMN2)89; Smn1+/-; Tg(SMNΔ7)4299; ROSA26rtTA; "new" Luci-TRE-SMN(B) mice (Stock No. 017597) were bred with FVB/NJ inbred mice (Stock No. 001800) for several generations, selecting for the "new" Luci-TRE-SMN(B) transgene and to remove the other transgenes/mutations. The resulting mice harboring only the "new" Luci-TRE-SMN(B) transgene were assigned Stock No. 017600. When maintaining the live "new" Luci-TRE-SMN(B) transgenic colony, transgenic mice may be bred with wildtype (noncarrier) mice from the colony or with FVB/NJ inbred mice (Stock No. 001800).
When using the STOCK Tg(tetO-SMN2,-luc)#bAhmb/J mouse strain in a publication, please cite the originating article(s) and include JAX stock #017600 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non Carrier for Tg(tetO-SMN2,-luc)#bAhmb |
Frozen Mouse Embryo | STOCK Tg(tetO-SMN2 -luc)#bAhmb/J | $2595.00 |
Frozen Mouse Embryo | STOCK Tg(tetO-SMN2 -luc)#bAhmb/J | $2595.00 |
Frozen Mouse Embryo | STOCK Tg(tetO-SMN2 -luc)#bAhmb/J | $3373.50 |
Frozen Mouse Embryo | STOCK Tg(tetO-SMN2 -luc)#bAhmb/J | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.